Study finds conflicting guidelines for statin use for black patients | PCSK9 inhibitor may cut heart, stroke risks in patients with CVD | Risk score predicts mortality for patients on heart transplant list
March 22, 2017
News for nuclear cardiology and cardiovascular imaging professionals
A study in JAMA Cardiology found conflicting medical guidelines on prescribing statin drugs to black patients. Data showed about 25% of blacks who would be eligible for a cholesterol-lowering statin medication under American College of Cardiology/American Heart Association guidelines would not be under new recommendations from the US Preventive Services Task Force.
A study in The New England Journal of Medicine showed use of the cholesterol-lowering drug Repatha, a PCSK9 inhibitor, along with statins, was associated with lower risks of heart attack, stroke, cardiovascular revascularization and extended major adverse cardiovascular events, but the drug's annual $14,523 price tag could put it out of reach for some. The study involved 27,564 adults who had experienced a heart attack or pain associated with narrowed arteries in the lower extremities.
Gain the Most In Demand Skills in Health Care GW's School of Medicine Health Sciences connects you with leading authorities in policy and health care in Washington, D.C. With programs in clinical research, health care quality and regulatory affairs, you gain the most in demand skills. Learn More
A study presented at the American College of Cardiology's Scientific Sessions showed that type 2 diabetes patients who received sacubitril/valsartan, a combination of neprilysin inhibitor and angiotensin II receptor blocker, had a greater reduction in A1C and a nonsignificant reduction in plasma glucose, compared with those on enalapril. Researchers based their findings on a cohort of 3,778 patients with diabetes and heart failure with reduced ejection fraction.
Survey data from 4,015 patients with non-metastatic breast cancer showed a lower risk of cardiovascular events and death from coronary heart disease among those who had a high level of physical activity, compared with those who had low activity levels. The study, presented at the American College of Cardiology's annual meeting, found patients who had moderate and intermediate activity levels also saw reduced CV risks.
The FDA has issued a letter alerting health care providers about the increased rates of major adverse cardiac events and stent thrombosis associated with use of Abbott Vascular's Absorb bioresorbable vascular scaffold, compared with the company's Xience metal stent. The agency advises clinicians to follow the instructions in the device's labeling for optimal device implantation and target heart vessel selection while it collaborates with Abbott to further analyze the causes of these high rates.
The American Health Care Act will undergo some changes before a House floor vote on Thursday, said Speaker Paul Ryan, R-Wis., who said he remains confident it will ultimately pass. Republican Study Committee leaders gave their support Friday after the White House agreed to include an option for states to integrate a work requirement into Medicaid programs, add a Medicaid block grant option and offer larger tax credits for lower-income, older Americans.